1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Ulcerative Colitis: Global Drug Forecast and Market Analysis to 2026

Ulcerative Colitis: Global Drug Forecast and Market Analysis to 2026

  • June 2018
  • 272 pages
  • ID: 5575022
  • Format: PDF
  • GlobalData
Up to $9896 off Until Oct 31st 2020


Table of Contents

Search Inside

Ulcerative Colitis: Global Drug Forecast and Market Analysis to 2026

The current Ulcerative Colitis (UC) market is overcrowded with cheap generic drugs for mild to moderate disease, as well as expensive biologics (anti-tumor necrosis factors [TNFs] and anti-integrins) and biosimilars for severe disease that are used as short- or long-term alternatives to surgical options.The R&D within this space consists of 10 late-stage pipeline drugs with four oral formulations, more convenient dosing frequencies, novel mechanisms of action (MOAs), and improved safety profiles and drug availability.

However, the pipeline products will be challenged by the increasing emergence of biosimilars, since the major brands will experience patent cliffs throughout the forecast period. Furthermore, all but one drug are being developed for moderate to severe UC, which could crowd the market place.

2016 sales for the Ulcerative Colitis (UC) market is estimated at approximately $5.4 billion across the 7MM, encompassing the US, the five major European Union countries (5EU: France, Germany, Italy, Spain, and UK), and Japan. Over the course of the 10-year forecast period, the Ulcerative Colitis (UC) market is expected to grow at a Compound Annual Growth Rate (CAGR) of 2.5% across the 7MM. Each of the 7MM are anticipated to grow, recording CAGRs of 2.7%, 1.2%, and 4.3% across the US, 5EU, and Japan, respectively.

At the end of 2026, the US will account for 80.4% of sales across the 7MM, while the 5EU and Japan, will account for around 16.1% and 3.4% of sales, respectively. The higher sales numbers for the US can be attributed to the higher prices of pharmaceuticals and the greater diagnosed prevalence of Ulcerative Colitis (UC) in the region, as well as the high annual cost of therapy (ACOT) of J&J’s Stelara and the anticipated ACOT of AbbVie’srisankizumab and Eli Lilly’s mirikizumab in the US market.

There are still high levels of unmet clinical need in the Ulcerative Colitis (UC) market, especially relating to the lack of safe and efficacious treatment alternatives.Current therapies have low safety profiles and can cause immunosuppression, leading to severe treatment-emergent adverse events (TEAE), which results in discontinuation of treatment in a significant number of patients.

The need for novel oral therapies, medical management of severe to fulminant patients, and lower cost of therapy are significant unmet needs in the Ulcerative Colitis (UC) space.

The report, "Ulcerative Colitis: Global Drug Forecast and Market Analysis to 2026", analyzes the Ulcerative Colitis (UC) treatment landscape and provides detailed insights into the market dynamics of this rapidly developing space.

The report specifically helps in answering -
- How will the Ulcerative Colitis (UC) market landscape in the 7MM (US, France, Germany, Italy, Spain, UK , and Japan) change from 2016-2026?
- What are the most promising late-stage pipeline drugs in UC?
- How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another and against existing treatment options?
- What are the greatest unmet needs in UC? Will the pipeline drugs fulfill these needs of the market?
- What are the largest opportunities in the Ulcerative Colitis (UC) landscape?

- Overview of UC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline UC market revenue from 2016-2026. ACOT and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting UC therapeutics sales in the 7MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global UC therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global UC therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the UC therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
30% Off


  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Cancer Immunotherapy Market - Growth, Trends, and Forecasts (2020 - 2025)

  • $ 4250
  • September 2020
  • 125 pages

Cancer Immunotherapy Market is expected to witness a CAGR of 12.2% during the forecast period. Certain factors that are driving the market growth include rising R&D activities, increasing effectivity and ...

  • Indiana
  • Cancer
  • Cancer Immunotherapy
  • Industry analysis
  • Cancer Incidence
  • Cancer Mortality


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on